IsoPlexis, a Branford, Conn.-based developer of single-cell functional proteomics, raised an additional $20m in its Series C financing, bringing the entire Series C round to $45m.
The round was led by Northpond Ventures with participation from existing investors.
The company intends to use the funds to drive the global commercial expansion of its IsoLight single-cell proteomic analysis platform.
Led by Sean Mackay, CEO and Co-Founder, IsoPlexis is focused on accelerating the fight against cancer and a range of the world’s toughest diseases with its single-cell detection systems.
The IsoLight single-cell system is used globally by leading biotech, pharma, and academic medical centers to solve critical challenges in cell therapy, cancer immunology, and inflammatory disease.
IsoPlexis has recently expanded its operational, manufacturing, and commercial team across the US, Europe, and Asia, with 130 employees. In 2020, the company will continue to expand its applications and release innovative products addressing high need research areas for its existing and future customer base, including products that address innate & myeloid function, tumor cell signaling, and other high need areas.